Multidrug-Resistant Gram-Negative Bacteria in Hospitals: New Guidelines
Gram-negative bacteria (MDRGNB) include common types such as E. coli that are present in human bowels. When these bacteria get into other parts of the body they can cause infections, including common infections such as cystitis or urinary tract infections. The bacteria can also be readily spread from person to person. Multidrug-resistant strains are resistant to most, or all, of the common antibiotics that are used to treat infections.
Professor Peter Wilson, professor of microbiology at University College London Hospitals NHS Foundation Trust and Chairman of the Working Group that developed the guidelines, explained: "Multi-resistant Gram negative bacteria have spread rapidly in some areas of Europe and threaten to do so in the UK. We conducted a wide ranging review of the evidence for preventing spread of these infections and have produced straightforward practical advice which we hope can be used by all grades of staff in every healthcare setting. If widely adopted we can prevent the problem becoming widespread."
The release of the new guidelines coincided with the first World Health Organization World Antibiotic Awareness Week. Much of the focus of the WHO's new campaign was on proper use of antibiotics to help prevent, or slow down, the emergence of MDRGNB. As these bacteria are already seen in the UK, authors of the guidelines said it is important to have systems in place to identify patients with these bacteria, and to make sure that they do not spread further in hospitals.
Dr. Jim Gray, Editor of the Journal of Hospital Infection, noted on the release of the guidelines, "Five or six years ago multi-resistant Gram-negative bacteria were a rarity in many UK hospitals. Now every hospital is seeing these bacteria regularly, as is evidenced by the large number of papers on the subject of MDRGNB that are published in the Journal of Hospital Infection."
As these guidelines are based on a synthesis of the best available evidence, Dr. Gray said the document "will play a crucial part in ensuring that all hospitals have ready access to a comprehensive toolkit to manage the very real threat posed by MDRGNB."
Image credit: Flickr.com
Published on : Tue, 24 Nov 2015
Print as PDF
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
Medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating.
FeaturesSV 300 is a state-of-the-art ventilator that’s simple to configure, easy to operate and versatile in use. It equips with extensive ventilation modes that can treats pediatric and adult patients with all acuity levels at ICUs and Intermediate Care.With...
Features The SynoVent E3 does not only include advanced ventilator functionality but also a modern, easy to use interface. The display can be configured to suit each clinician’s taste and needs, and gives quick and easy control over ventilator parameters...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...